CRIS Current Research Information System

MARTELLO, MARINA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 1.898
EU - Europa 1.420
AS - Asia 748
AF - Africa 126
SA - Sud America 5
OC - Oceania 1
Totale 4.198
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 1.888
IT - Italia 449
CN - Cina 299
GB - Regno Unito 264
SG - Singapore 211
SE - Svezia 183
DE - Germania 168
IN - India 105
VN - Vietnam 80
IE - Irlanda 69
RU - Federazione Russa 68
FR - Francia 43
TG - Togo 41
CI - Costa d'Avorio 40
FI - Finlandia 27
BG - Bulgaria 26
ZA - Sudafrica 23
UA - Ucraina 22
NG - Nigeria 21
CH - Svizzera 20
EE - Estonia 19
NL - Olanda 15
AT - Austria 12
BE - Belgio 11
JO - Giordania 11
CA - Canada 10
ID - Indonesia 10
HK - Hong Kong 9
IR - Iran 9
ES - Italia 7
PH - Filippine 7
RO - Romania 5
TR - Turchia 4
BR - Brasile 3
HR - Croazia 3
CZ - Repubblica Ceca 2
PL - Polonia 2
RS - Serbia 2
AU - Australia 1
BD - Bangladesh 1
CL - Cile 1
CY - Cipro 1
EC - Ecuador 1
LT - Lituania 1
LU - Lussemburgo 1
NO - Norvegia 1
TN - Tunisia 1
UZ - Uzbekistan 1
Totale 4.198
Salva come PNG Salva come JPEG
Città #
Chandler 275
Southend 243
Fairfield 188
Singapore 172
Ashburn 154
Bologna 129
Ann Arbor 121
Woodbridge 78
Houston 76
Wilmington 76
Dublin 69
Seattle 69
Princeton 66
Cambridge 65
Boardman 47
Santa Clara 47
Lomé 41
Abidjan 40
Milan 39
Dong Ket 38
Hyderabad 38
Beijing 36
New York 36
Bremen 31
Nanjing 31
Fabriano 27
Sofia 26
Helsinki 25
Westminster 23
Turin 22
Abeokuta 20
Berlin 20
Padova 20
Salsomaggiore Terme 20
Redmond 18
Los Angeles 15
Bern 14
Medford 14
Shenyang 14
Redwood City 12
Saint Petersburg 12
Amman 11
Brussels 11
Florence 11
Jinan 11
Vienna 11
Jakarta 10
Rome 10
Amsterdam 9
Hong Kong 9
Mondolfo 9
Wuhan 9
Nanchang 8
Des Moines 7
Hebei 7
Nuremberg 7
Toronto 7
Yubileyny 7
Zhengzhou 7
Changsha 6
Coimbatore 6
Dearborn 6
Falls Church 6
Guangzhou 6
Kuban 6
Monmouth Junction 6
Norwalk 6
San Diego 6
Shanghai 6
Haikou 5
Hangzhou 5
Jiaxing 5
Munich 5
Naples 5
Paris 5
Reggio Emilia 5
Riola 5
Taizhou 5
Tianjin 5
Como 4
Modena 4
Olalla 4
Parma 4
San Francisco 4
San Lazzaro Di Savena 4
Boydton 3
Cagliari 3
Carpi 3
Casalecchio di Reno 3
Chengdu 3
Frankfurt am Main 3
Fuzhou 3
Geneva 3
Kunming 3
Lanzhou 3
Leawood 3
Mülheim 3
Pianoro 3
Pune 3
Shenzhen 3
Totale 2.847
Salva come PNG Salva come JPEG
Nome #
The genetic and genomic background of multiple myeloma patients achieving complete response after induction therapy with bortezomib, thalidomide and dexamethasone (VTD) 162
A 41-gene signature predicts complete response (CR) to Bortezomib-Thalidomide-Dexamethasone (VTD) as induction therapy prior to autologous stem-cell transplantation (ASCT) in multiple myeloma (MM). 161
Bortezomib- and thalidomide-induced peripheral neuropathy in multiple myeloma: clinical and molecular analyses of a phase 3 study. 152
A 41-Gene Signature Predicts Complete Response (CR) to Bortezomib-Thalidomide-Dexamethasone (VTD) As Induction Therapy Prior to Autologous Stem-Cell Transplantation (ASCT) in Multiple Myeloma (MM) 144
Hypoxia inducible factor-1 alpha as a therapeutic target in multiple myeloma. 143
Current and emerging triplet combination therapies for relapsed and refractory multiple myeloma 143
Disease-specific derangement of circulating endocannabinoids and n-acylethanolamines in myeloproliferative neoplasms 141
Opposite activation of the Hedgehog pathway in CD138+ plasma cells and CD138-CD19+ B cells identifies two subgroups of patients with multiple myeloma and different prognosis 138
Prognostic impact of serial measurements of serum-free light chain assay throughout the course of newly diagnosed multiple myeloma treated with bortezomib-based regimens 136
A real-world efficacy and safety analysis of combined carfilzomib, lenalidomide, and dexamethasone (KRd) in relapsed/refractory multiple myeloma 136
Treatment optimization for Multiple Myeloma: schedule-dependent synergistic cytotoxicity of pomalidomide and carfilzomib in an in vitro and ex-vivo model 134
Genomic characterization of the putative myeloma stem cells clone reveals alterations possibly correlated with the origin of disease. 128
Correlation between eight-gene expression profiling and response to therapy of newly diagnosed multiple myeloma patients treated with thalidomide–dexamethasone incorporated into double autologous transplantation 125
Clonal and subclonal TP53 molecular impairment is associated with prognosis and progression in multiple myeloma 125
Novel agent-based salvage autologous stem cell transplantation for relapsed multiple myeloma 123
High Number of Copy Number Alterations and Over-Expression of Genes Involved in the Response Mechanisms to Genotoxic Stress Both Characterize Newly Diagnosed Multiple Myeloma (MM) Patients Carrying Amplified MDM4 and/or Deleted p53 123
Inter-Cell Networking Profiling Enables Comprehensive Characterization of Immune-Mediated Activity of Anti-CD38 Therapy through Ex-Vivo Analysis of Multiple Myeloma Patients 120
PET/CT Improves the Definition of Complete Response and Allows to Detect Otherwise Unidentifiable Skeletal Progression in Multiple Myeloma 119
HIF-1α inhibition blocks the cross talk between multiple myeloma plasma cells and tumor microenvironment 118
Maintenance therapy with bortezomib and dexamethasone after autotransplantation for high-risk multiple myeloma 113
HIF 1 Alpha: A Suitable Target for Multiple Myeloma 112
SIRT regulates the molecular interaction between c-MYC and HIF-1 alpha in multiple myeloma 105
Gene expression analysis of newly diagnosed Multiple Myeloma (MM) patients carrying amplified MDM4 and/or deleted p5 102
HIF-1a INHIBITION PROMOTES CELL CYCLE ARREST IN MULTIPLE MYELOMA 99
null 98
Impact Of p53 Impaired Function On Outcomes Of Multiple Myeloma Patients Carrying Deleted TP53 and/Or Amplified MDM4 97
Therapeutic targeting of hypoxia and hypoxia-inducible factor 1 alpha in multiple myeloma 97
High CNA level and over-expression of genes involved in response mechanisms to genotoxic stress characterize newly diagnosed Multiple Myeloma (MM) patients carrying amplified MDM4 and/or deleted TP53 95
Droplet digital polymerase chain reaction for the assessment of disease burden in hairy cell leukemia 88
BoBafit: A copy number clustering tool designed to refit and recalibrate the baseline region of tumors’ profiles 86
VarianThinker: a classification method to confidently approach the mutation heterogeneity in Multiple Myeloma 84
Identification of a Maturation Plasma Cell Index through a Highly Sensitive Droplet Digital PCR Assay Gene Expression Signature Validation in Newly Diagnosed Multiple Myeloma Patients 74
A Methodologically Updated De-Novo Extraction of Copy Number Signatures in Multiple Myeloma: Clinical Significance and Putative Aetiologies 73
Integrative analysis of the genomic and transcriptomic landscape of double-refractory multiple myeloma 68
The ALLgorithMM: How to define the hemodilution of bone marrow samples in lymphoproliferative diseases 61
Single-Cell DNA Sequencing Reveals an Evolutionary Pattern of CHIP in Transplant Eligible Multiple Myeloma Patients 52
Long term follow-up of humoral and cellular response to mRNA-based vaccines for SARS-CoV-2 in patients with active multiple myeloma 44
Droplet digital polymerase chain reaction for the assessment of disease burden in hairy cell leukemia 39
OAB-057: Temporal-weight estimation of the copy number alterations of of 1384 Multiple Myeloma patients defines an ancestrality index impacting patients survival 31
Circulating Multiple Myeloma Cells (CMMCs) as Prognostic and Predictive Markers in Multiple Myeloma and Smouldering MM Patients 30
Multi-dimensional scaling techniques unveiled gain1q&loss13q co-occurrence in Multiple Myeloma patients with specific genomic, transcriptional and adverse clinical features 29
OAB-006: A novel algorithm to identify, characterize and define the prognostic impact of complex catastrophic events in Multiple Myeloma 24
Rare, but complex chromosomal rearrangements, defined "Chromoanagenesis”, caused by single-step or stepwise catastrophic genomic events, significantly impact on Multiple Myeloma patients 24
High levels of CRBN isoform lacking IMiDs binding domain predicts for a worse response to IMiDs-based upfront therapy in newly diagnosed myeloma patients 24
Abstract 2700: Negative selective pressure exerted by maintenance therapy promotes the extinction of sub-clones carrying high-risk lesions in multiple myeloma 14
High level of circulating cell-free tumor DNA at diagnosis correlates with disease spreading and defines multiple myeloma patients with poor prognosis 5
Minimal Residual Disease Assessment Within the Bone Marrow of Multiple Myeloma: A Review of Caveats, Clinical Significance and Future Perspectives 1
Totale 4.340
Salva come PNG Salva come JPEG
Categoria #
all - tutte 13.414
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 13.414
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/2020378 0 0 0 0 0 0 85 86 88 43 37 39
2020/2021397 72 21 10 15 17 27 19 33 62 17 18 86
2021/2022794 73 41 37 62 62 41 27 50 40 99 120 142
2022/20231.073 96 140 47 170 81 80 29 57 157 48 84 84
2023/2024486 39 46 43 39 31 97 26 88 14 19 24 20
2024/2025721 98 132 112 110 121 61 87 0 0 0 0 0
Totale 4.340